40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

Autor: Ljung, R. *, Karim, F.A., Saxena, K., Suzuki, T., Arkhammar, P., Rosholm, A., Giangrande, P.
Zdroj: In Journal of Thrombosis and Haemostasis July 2013 11(7):1260-1268
Databáze: ScienceDirect